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ABSTRACT 
This is an up-to-date review on the holism of ophthalmology, covering the associations between eyes and 
systemic diseases.  
 
Ophthalmology teaching in the undergraduate medical curriculum is often very brief, which seems reasonable 
in view of other specialties such as internal medicine which have many life-and-death issues and numerous 
diseases across a wide spectrum of subspecialties. By contrast, ophthalmology gives the impression of being 
more specialized. However, the value which vision holds in people’s hearts is usually underestimated when 
compared to life or limb. Moreover, the severity of visual impairment in relation to its impact on daily life is also 
often not proportional; in other words, mild visual impairment may have a detrimental effect on daily life, 
functionally and emotionally.  
 
This review aims to provide an overview of ocular pathologies that are associated with systemic diseases with 
emphasis on cardiovascular and autoimmune conditions. In addition, we discuss the potential role of retinal 
microvascular analysis in the prevention and management of cardiovascular diseases, which has been gaining 
attention in recent years. 
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Introduction 
A survey of 11,000 people in 11 countries, 
conducted by Bausch & Lomb (one of the eye-care 
giants), demonstrated that rather than losing sight, 
67% of people would rather lose 10 years of life, 
68% would rather sacrifice a limb, 78% would rather 
lose their ability to hear and 79% would rather lose 
their sense of taste.1 However, while facing 
numerous life-and-death issues in the medical field, 
we often forget that there are things that a patient 
may weigh even more importantly than life – such as 
vision. 
 
Vision is the dominant sensory modality that the 
majority of human beings use to interpret the world. 
The ability to see provides us with a sense of 
security. We often only appreciate this after it’s 
gone, which may occur even following minor issues, 
such as the changes in refractive error and the need 
for new glasses. Nevertheless, the “minor issue” of 
uncorrected refractive error is the commonest 
global cause of moderate-to-severe visual 
impairment according to World Health 
Organization,2 even though refractive-error 
correction is neither difficult nor expensive. 
 
There is also relatively less emphasis in our 
undergraduate curriculum on the active detection 
and timely referral of ocular presentations in 
systemic diseases and the correlation of ocular 
features with systemic diseases. Therefore, this 
review seeks to provide a non-exhaustive overview 
of the holism of ophthalmology to attempt to, at 
least in part, redress this balance. 
 
Methods 
The studies that are cited in this clinical review were 
retrieved from PubMed and Ovid (Embase). Titles 
and abstracts retrieved from search strategies were 
screened based on the sequence of “sort by 
relevance”, then full texts were accessed for 
selected studies. Three main search methods were 
applied: 
 
1)   Usage of “all fields” of keywords pertaining to 
particular anatomical structures of the eye (e.g. 
retina) and “systemic diseases” or the specific 
name of known associated systemic diseases 
(e.g. “diabetes mellitus”), with or without the 
use of filters such as “review”, “meta analysis”, 
“published in the last 5 years” and “published 
in the last 10 years”. Relevant studies with 
higher evidence levels such as meta-analyses 
and reviews, which can portray the holism of 
ophthalmology through the association with 
systemic diseases, were given highest priority 
during selection of references.  
 
2)   Single search terms, e.g. “Vogt Koyanagi 
Harada disease”, “drug-induced uveitis” and 
“peripheral ulcerative keratitis”, applied to “all 
fields” were used only once a specific system 
disease was confirmed to have 
ophthalmological associations and further 
information was desired.  
 
3)   To provide evidence of specific facts such as ten 
anatomic layers of retina, more specific 
keywords like “ten layers of retina” under “all 
fields” with filters such as “review” were used.  
 
Some references were manually searched from the 
studies that were selected in the first round of 
abstract screening and some from the “similar 
articles” and “find similar” sections on PubMed and 
Ovid (Embase) respectively. Relevant websites, 
mainly http://emedicine.medscape.com and 
http://www.uptodate.com, with contents strongly 
evidence-based, were cited.  
 
Emphasis has been placed on cardiovascular and 
autoimmune diseases, as these two groups can be 
commonly encountered in all specialties due to the 
high prevalence of cardiovascular diseases and the 
multi-systemic involvement of autoimmune 
diseases. 
 
Holism of Ophthalmology (from posterior to 
anterior segment)  
A.   CARDIOVASCULAR DISEASES 
1.   Retina 
The ocular component that is best known to have 
associations with cardiovascular disease is the 
retina. The retina, the innermost layer of the globe, 
is divided into outer retinal pigment epithelium 
(RPE) and inner neurosensory layer.3 It is associated 
with diabetes mellitus, hypertension, 
arteriosclerosis, coronary heart disease and 
cerebrovascular diseases. The uniqueness of being 
able to view the retinal microvasculature in vivo 
easily, directly, and non-invasively has greatly 
contributed to the study of cardiovascular diseases 
and the potential role of retinal microvasculature 
properties in predicting their development4 and 
progression.5-6 
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(i) Diabetic Retinopathy 
Diabetic retinopathy (DR), the most important ocular 
manifestation of diabetes mellitus, is classified into 
non-proliferative retinopathy, proliferative 
retinopathy and maculopathy.7 Patients are usually 
asymptomatic until advanced stages where blurring 
of vision, metamorphopsia, floaters and sudden 
visual loss may occur.8 The severity of retinopathy is 
related to the duration of diabetes, a younger age 
at diagnosis, higher glycosylated hemoglobin 
levels, higher systolic blood pressure, use of insulin, 
presence of proteinuria, and low body mass.9 
Therefore, the signs of diabetic retinopathy (Table 
1), of which most are easily detected on direct 
fundoscopy, should be actively sought, especially in 
those with the aforementioned risk factors.7, 8, 10  
 
Table 1 – Signs of Different Types of Diabetic 
Retinopathy 7, 8, 10 
Types of DR Signs 
Non-
proliferative  
•   Microaneurysms (earliest 
clinical sign). 
•   Dot and blot hemorrhages. 
•   Hard exudates. 
•   Soft exudates. 
•   Venous beading. 
•   Intraretinal microvascular 
abnormalities (IRMA).  
Proliferative •   Neovascularization (hallmark). 
•   Preretinal hemorrhage. 
•   Vitreous hemorrhage. 
•   Fibrovascular tissue 
proliferation.  
•   Tractional retinal detachment. 
•   Macular oedema. 
Diabetic 
Maculopathy/ 
Diabetic 
macular 
oedema 
(DME)  
Clinically significant if any of the 
below occurs: 
•   Retinal thickening occurs at or 
within 500 microns of the 
center of macula. 
•   Hard exudates at or within 500 
microns of the center of 
macula, if associated with 
thickening of adjacent retina 
but not residual hard exudates 
remaining after disappearance 
of retinal thickening.  
•   Zone(s) of retinal thickening at 
least 1 disc area, any part of 
which is within 1 disc diameter 
of the center of macula. 
 
Visual impairment and blindness are still major 
concerns in type I diabetes (DM1), despite strict 
glycemic control and use of laser 
photocoagulation4. The Wisconsin Epidemiologic 
Study of Diabetic Retinopathy (WESDR) showed that 
wider retinal arterioles were associated with 10-fold 
increase in the incidence of DR in patients with type 
2 diabetes (DM2) [odds ratio, OR=1.78].11 This was 
further supported by a prospective cohort study 
(OR=4.79).12 A cross-sectional study demonstrated 
that lower retinal fractals (a self-similarity 
characteristic of retinal vasculature where the overall 
shape and structure will persist regardless of 
changes in magnification)13 were associated with 
proliferative retinopathy (OR=1.45), neuropathy 
(OR=1.42), nephropathy (OR=1.39), but not 
macrovascular disease.14 Therefore, retinal arteriolar 
caliber and fractals might be useful in predicting the 
microvascular damage caused by diabetes, without 
being limited to intrinsic retinal changes. 
 
(ii) Retinal Venous Occlusion 
Retinal venous occlusion (RVO) is the second most 
common retinal venous disease after DR and an 
important cause of visual morbidity and blindness.15 
Branch RVO can be asymptomatic or produce 
metamorphopsia or relative scotoma, and on 
occasion may only be detected incidentally on 
fundoscopy.16 Central RVO classically presents as 
sudden painless monocular visual loss or dense 
central scotoma, although non-ischemic type may 
be more subtle and present as intermittent episodes 
of blurred vision.16 Retinal signs of RVO are easily 
detected on direct ophthalmoscopy (Table 2) and 
hence can be diagnosed clinically.15, 17  
 
Table 2 – Clinical Signs and Systemic Risk Factors of 
Retinal Venous Occlusion15, 17 
Clinical 
Signs 
•   Flame-shaped hemorrhages. 
•   Dot and blot hemorrhages. 
•   Cotton wool spots. 
•   Venous tortuosity. 
•   Macular oedema. 
•   Optic disc swelling in the affected 
perfusion region. 
Systemic 
Risk 
factors 
•   Metabolic syndrome (e.g. diabetes 
mellitus, hypertension, 
hyperlipidemia). 
•   Arteriosclerosis. 
•   Vascular cerebral stroke. 
•   Blood hyperviscosity. 
•   Thrombophilia. 
•   Smoking.  
•   Systemic inflammatory diseases 
(e.g. vasculitis and Behcet’s 
syndrome). 
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A 2014 meta-analysis evidenced that, apart from the 
immutable risk factor of advancing age, the other 
risk factors for RVO are all systemic (Table 2). 15,17 
Metabolic syndrome greatly increases the risk of 
RVO, especially if end-organ damage due to 
diabetes or hypertension has occurred.15 The role of 
thrombophilic risk factors remains controversial, 
although congenital thrombophilic diseases, 
hyperhomocysteinemia and anticardiolipin 
antibodies can all increase the risk of RVO.15 
Therefore, in elderly patients with cardiovascular risk 
factors that present with sudden painless visual loss, 
RVO should be among the top differential 
diagnoses.  
 
(iii) Hypertensive Retinopathy (HR) 
In individuals with elevated BP, visual loss can occur 
due to hypertensive retinopathy (HR).18 Hence, 
ophthalmoscopy has long been adopted as part of 
the evaluation of hypertensive patients.18, 19 HR can 
be classified into mild, moderate and malignant 
according to population-based data (Table 3).18 
Associations with clinical CVA, subclinical CVA, 
cognitive decline, coronary heart disease, 
congestive heart failure, and cardiovascular 
mortality may exist once patients develop mild HR 
and increase proportionally with severity.18, 20 An 
algorithm has been designed to provide specific 
management plan according HR severity.18 
 
Table 3 – Classification of Hypertensive 
Retinopathy18 
Severity Retinal Signs 
None No detectable signs. 
Mild Generalized arteriolar narrowing, focal 
arteriolar narrowing, arteriovenous 
nicking, opacity (“copper wiring”) of 
arteriolar wall, or a combination of 
these signs  
Moderate Hemorrhage (blot, dot, or flame-
shaped), microaneurysm, cotton-wool 
spot, hard exudate, or a combination 
of these signs. 
Malignant Signs of moderate retinopathy plus 
swelling of the optic disk *. 
* = Anterior ischemic optic neuropathy, 
characterized by unilateral swelling of the optic 
disk, visual loss, and sectorial visual- field loss, 
should be ruled out.  
 
(iv) Transient monocular visual field loss (TMVL) 
Transient monocular visual field loss (TMVL), 
typically sudden and painless,21 is divided into 
embolic (eTMVL) and non-embolic 
(neTMVL).22  Visual field loss can be sectorial 
(‘‘curtain effect’’) or altitudinal, which strongly 
suggests vascular etiology.23,24 This may follow the 
horizontal meridian in a branch retinal arterial 
occlusion or follow the vertical meridian in a 
posterior ciliary arterial occlusion, which will also 
require investigation to exclude a possible occipital 
stroke 22.  
 
eTMVL is associated with increased stroke risk and 
hence requires urgent assessment.22 The source of 
emboli can be the heart, carotid artery or aorta.22 
There might be co-existing atrial fibrillation, past or 
recent cardiac ischemia, metabolic syndrome and 
hypercoagulability.22  
 
For central retinal arterial occlusion (CRAO), 
fundoscopy can be carried out to detect a fibrin-
platelet thrombus or cholesterol embolus (a 
Hollenhorst plaque) within the lumen of the central 
retinal artery (15-29% detection rate on direct 
ophthalmoscopy) and retinal infarction with a cherry 
red spot (during acute phase, 90% of all cases with 
permanent visual loss and 59% of transient 
cases).22,25 Other acute phase signs of CRAO include 
retinal opacities (59%), visible emboli (15%), disc 
oedema (11%), disc pallor (11%), attenuated retinal 
arteries (11%), cotton-wool spots (7%), and 
attenuated veins (7%).22  
 
neTMVL is thought to be associated with retinal 
vasospasm, which, if observed during direct 
fundoscopy, is diagnostic.22 Hence, a broader 
differential diagnoses of secondary vasospasm 
should be considered when suspecting neTMVL – 
including autoimmune diseases (e.g. giant cell 
arteritis, systemic lupus erythematosus and 
rheumatoid arthritis); infectious diseases (e.g. 
bacterial meningitis); vascular diseases (e.g. 
subarachnoid hemorrhage and intracerebral 
hemorrhage); and other causes (e.g. malignancy 
and beta blocker usage).22 
 
(v) Cardiovascular Diseases  
According to the World Health Organization, 
cardiovascular disease, particularly ischemic heart 
disease, cerebrovascular diseases and diabetes 
mellitus are within the top 10 causes of mortality 
since 2000 and will continue as such at least till 
2030, irrespective of the income levels.26, 27  
 
A 2009 review summarized the relationship between 
retinal vascular caliber with various systemic factors, 
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such as age, hypertension, obesity, coronary artery 
disease, smoking, and systemic inflammation.28 
Recent data also demonstrated a potential genetic 
contribution.28  
 
Retinal vascular caliber is usually quantified on 
digitized or digital retinal images with computer-
assisted programs, and cannot be accurately 
measured clinically as yet.29 However, it is important 
to be aware of the rapidly growing importance of 
the role of non-invasive retinal microvasculature 
analysis on the prediction, prevention and 
monitoring of cardiovascular diseases, which has the 
potential for significant impact on morbidity and 
mortality in the future.6,28 
 
The reduction in flicker light-induced retina-arterial 
vasodilation, which has been shown to be 
endothelium- and nitric-oxide-dependent, has also 
been shown to be associated with cardiovascular 
risk factors, such as diabetes mellitus.6 Multiple 
reviews concluded that since endothelial 
dysfunction precedes the development of 
morphological vascular changes, the assessment of 
endothelial function could have a diagnostic value, 
especially in patients with cardiovascular risk 
factors.6,29 
 
2.   Optic nerve  
(i) Ischaemic optic neuropathy (ION) 
Ischaemic optic neuropathy (ION), a major cause of 
blindness or severe visual impairment, was 
discussed in detail in a 2009 review.30 Non-arteritic 
anterior ischemic optic neuropathy (NA-AION) is by 
far the most common type among the 6 distinct 
clinical categories of ION and one of the most 
prevalent and visually crippling diseases in the 
middle-aged and elderly.30 NA-AION is associated 
with arterial hypertension, arterial hypotension, 
diabetes mellitus, hyperlipidemia, ischemic heart 
disease, atherosclerosis, and arteriosclerosis.30 The 
majority of cases present with sudden, painless 
visual deterioration, particularly loss of the nasal 
fields, discovered upon waking up in the 
morning.30,31 Photophobia is common in bilateral 
cases.30 Other signs which may be elicited during 
clinical examination include relative afferent 
pupillary defects in unilateral cases, optic disc 
oedema, splinter hemorrhage on the optic disc or in 
the peripapillary region, serous retinal detachment, 
and macular edema.30 
 
Arteritic AION (A-AION), although less common, is 
an ocular emergency that is almost invariably caused 
by giant cell arteritis (GCA), with the single strongest 
risk factor being age.32 GCA, which is associated 
with increased cardiovascular risk, is mainly a clinical 
diagnosis and has to be actively sought, especially 
in elderly patients, based on the American College 
of Rheumatology 1990 criteria (Table 4), which have 
a sensitivity of 95.3% and specificity of 90.7%.33 A-
AION requires early diagnosis and immediate 
treatment with systemic high dose corticosteroids to 
reduce the risk of further visual loss.31, 34  
 
 
 
 
 
 
 
Table 4 – The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis33 
Old Criteria of 5  Classification Tree of 6 Criteria 
•   age greater than or equal to 50 years at 
disease onset. 
•   new onset of localized headache. 
•   temporal artery tenderness or decreased 
temporal artery pulse. 
•   * elevated erythrocyte sedimentation rate 
(Westergren) greater than or equal to 50 
mm/hour. 
•   biopsy sample including an artery, showing 
necrotizing arteritis, characterized by a 
predominance of mononuclear cell infiltrates 
or a granulomatous process with 
multinucleated giant cells. 
•   age greater than or equal to 50 years at disease 
onset. 
•   new onset of localized headache. 
•   temporal artery tenderness or decreased temporal 
artery pulse. 
•   biopsy sample including an artery, showing 
necrotizing arteritis, characterized by a predominance 
of mononuclear cell infiltrates or a granulomatous 
process with multinucleated giant cells. 
•   * scalp tenderness. 
•   * claudication of the jaw or tongue or on deglutition. 
* = Differences between old and new criteria, either removed or newly added. 
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B.   AUTOIMMUNE DISEASES 
1.   Uvea 
The uvea consists of the iris, ciliary body and 
choroid.35 Uveitis, most often unilateral and 
idiopathic, is characterized by the potentially 
sight-threatening intraocular inflammation of the 
uveal tract, although inflammation of adjacent 
tissues, such as the retina, optic nerve and 
vitreous humor may also occur.36 Uveitis is the 
commonest ophthalmological finding in the 
practice of rheumatology and clinical 
immunology and requires urgent evaluation by 
ophthalmologists due to the risk of blindness if 
treatment is delayed.35 
 
Classification is most commonly based on the 
primary anatomical site of inflammation.37-43 The 
International Uveitis Study Group has also 
proposed a simplified clinical classification based 
on suspicion of infection in order to facilitate the 
evaluation and diagnosis of uveitis.40, 44 The 
presentation of uveitis and its relationship with 
systemic diseases is summarized in Table 5.35,40-
42,45,46§ 
 
Table 5 – Presentations of Uveitis and Its Relationship with Systemic Diseases 
Types of 
Uveitis 
Ocular symptoms and signs Relationship with systemic diseases 
Anterior 
uveitis  
•   Eye redness. 
•   Blurred vision. 
•   Photophobia. 
•   Periorbital pain. 
•   Floaters. 
•   Leukocytes in anterior chamber (non-
specific). 
•   Haze/Flare, i.e. protein accumulation in 
aqueous humor (Slit-lamp). 
•   Dependent on underlying disease 
course (e.g. ankylosing spondylitis). 
•   Independent of underlying disease 
course (e.g. inflammatory bowel 
disease). 
Intermediate 
uveitis 
•   Similar to posterior uveitis. 
•   Leukocytes in vitreous humor (diagnostic). 
•   Exudates/”snowbanks” (signifies pars 
planitis; detected by scleral depression). 
•   Develop systemic disease within 10 
years (e.g. multiple sclerosis). 
Posterior 
uveitis 
•   Blurred vision to severe visual loss.  
•   Floaters. 
•   Flashes. 
•   Less likely to be red and painful. 
•   Evidence of active chorioretinal 
inflammation (diagnostic). 
•   Cardinal part of the underlying 
systemic disease (e.g. Behcet’s 
disease). 
Pan uveitis •   Inflammation detected simultaneously of 
all layers of uvea (anterior chamber, 
vitreous, retina/ choroid). 
•   Combination of symptoms and signs 
above. 
•   Cardinal part of the underlying 
systemic disease (e.g. Vogt-Koyanagi 
Harada syndrome and Behcet’s 
disease). 
As the underlying systemic causes of uveitis are 
usually autoimmune or inflammatory diseases, 
corticosteroids and other immunosuppressants 
are often indicated and this may lead to side 
effects, such as cataract, glaucoma, central 
obesity, metabolic diseases, opportunistic 
infections, and liver and renal toxicity. 
 
Although more than half of uveitis cases have no 
identifiable cause, all types of uveitis (based on 
anatomic classification) can be drug-induced.47, 48 
The culprits can be systemic, intraocular or topical 
medications that are commonly encountered, 
such as cidofovir, sulfonamides, 
bisphosphonates, anti-vascular endothelial 
growth factor, triamcinolone, metipranolol, 
theBacillus Calmette-Guérin vaccine and the 
MMR vaccine.47 The strength of association 
between causative drugs and uveitis are scored 
and categorized according to Naranjo’s 
Classification Criteria.47, 49 
 
2.   Cornea, Conjunctiva and Eyelid 
Many systemic diseases that affect the cornea 
also involve the conjunctiva. Systemic 
inflammatory disorders, which might be life-
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threatening, such as connective tissue diseases, 
autoimmune diseases of the lacrimal system, and 
graft-versus-host-disease (GVHD) can affect the 
cornea and potentially lead to blindness.50, 51 
Prompt referral to an ophthalmologist 
consultation is therefore recommended.50-57   
 
(i) Keratoconjunctivitis sicca (KCS) 
The commonest ocular finding in these patients is 
keratoconjunctivitis sicca (KCS) 50,51. KCS can be 
synonymous with dry eye disease (DED) or refer 
only to DED caused by aqueous tear deficiency.50, 
58-60  Dry eye disease (DED) is a multifactorial 
disease that results in symptoms of discomfort, 
visual disturbance, and tear film instability with 
potential damage to the ocular surface, 
accompanied by increased osmolarity of the tear 
film and inflammation.58 The common symptoms 
are dryness, irritation, foreign body sensation, 
photophobia, and itching.61  
 
DED is usually classified by aetiologies, which can 
be due to pathological or systemic factors. It is 
generally divided into aqueous deficiency, which 
largely depends on lacrimal gland function (e.g. 
Sjogren syndrome, ageing, sarcoidosis, 
lymphoma and cicatricial diseases) and 
evaporative causes (e.g. meibomian gland 
dysfunction, disorders of lid aperture and globe 
congruity, contact lens wear, allergic 
conjunctivitis and vitamin A deficiency).58,62-63 
DED is usually diagnosed via ocular surface dye 
staining, fluorescein tear break-up time, the 
Schirmer test or symptom questionnaires, 
although newer methods with higher sensitivity 
and specificity have been reported, e.g. tear film 
osmolarity, tear fluid protein immunoassays, and 
fluorescein tear clearance.64,65 A diagnostic 
algorithm was designed and deemed better than 
single test alone.65,66  McMonnies questionnaire is 
one of the earliest and most widely used DED 
screening tools with 87 - 98% sensitivity 
reportedly and 87 – 97% specificity.67,68-69 
 
(ii) Other Corneal/Conjunctival/Eyelid 
Involvements 
In GVHD, apart from KCS, the cornea may show 
filamentary keratitis, superficial punctate keratitis, 
corneal ulcers, and peripheral corneal melting 
which may lead to perforation in severe cases.51 
Severe dry eye syndrome may occur and later 
develop conjunctival scarring, keratinization, and 
cicatrization, which can be detected by on clinical 
examination.51 Eyelid changes leading to 
scleroderma-like appearance may occur, 
including poliosis (loss of melanin in eyelashes), 
madarosis (loss of eyelashes), vitiligo, 
lagophthalmos, and entropion.51 Nevertheless, all 
the layers of the eye can be involved in ocular 
GVHD, although posterior eye involvement is 
very rare.51 
 
Peripheral ulcerative keratitis (PUK) although rare, 
might be an indicator of more severe and 
widespread systemic vasculitis.50  Sclerosing 
keratitis, the peripheral thickening and 
opacification of the corneal stroma adjacent to 
the site of inflammation secondary to scleritis, 
may be associated with rheumatoid arthritis.50,70 
Calcific band keratopathy, a chronic degenerative 
condition characterized by the deposition of 
grayish opacities in the superficial layers of the 
cornea, most frequently in the interpalpebral 
zone, is commonly associated with chronic ocular 
inflammatory diseases.50, 71 It is one of the 
commonest ocular complications (38%) of 
juvenile idiopathic arthritis.72 
  
3.   Sclera 
Scleritis is an uncommon, heterogeneous group 
of diseases characterized by inflammation of the 
sclera, which may be caused by local or systemic 
infections or immune mediated diseases.73,74 
Rheumatoid arthritis remains the commonest 
disease that is associated with all types of 
scleritis.74 There are various etiologies of scleritis 
but the systemic autoimmune or vasculitic 
diseases are implicated in half of all cases.74-76 All 
of these cause scleral inflammation, which results 
to readily detectable changes in the visible coats 
of episclera and conjunctiva.  However, 
episcleritis and scleritis may be distinguished 
based on history and physical examinations.77 
Both scleritis and episcleritis can present as red 
eye.77 However, scleritis is more likely to present 
as a sudden onset of deep, severe periorbital pain 
with radiation to the temple and jaw and often 
wakes patients at night. 50% of cases have 
underlying systemic symptoms.  By contrast, 
episcleritis is usually painless and less likely to 
have systemic symptoms.77 
 
4.   Orbit, Extraocular muscles and Eyelids 
(i) Graves’ Ophthalmopathy (GO) 
Graves’ ophthalmopathy (GO), also known as 
thyroid eye disease, is the commonest (25%) 
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extra-thyroidal manifestation of Grave’s Disease 
(GD).78 Bilateral GO usually occurs simultaneously 
or within 18 months of hyperthyroidism in GD, 
although occasionally GO and GD can happen 
separately with many years in between.79 Clinical 
presentations of GO and GD are described in 
table 6.80 Cigarette smoking is the strongest 
modifiable risk factor of GO and exists in dose-
dependence relationship, so smoking history 
should be taken in detail.81 
 
Table 6 – Clinical Presentations of Grave’s Ophthalmopathy (GO) and Grave’s Disease (GD) 
Diseases Symptoms Signs 
GO •   Dryness. 
•   Gritty ocular sensation,  
•   Photophobia. 
•   Excessive tearing, 
•   Double vision. 
•   Pressure sensation behind the 
eyes. 
•   Pain. 
•   Edema and erythema of the periorbital tissues and 
conjunctivae. 
•   Proptosis. 
•   Corneal ulcer (due to lagophthalmos). 
•   Upper eyelid retraction. 
•   Lid lag on downgaze (von Graefe sign). 
•   Absence of forehead creases on upgaze (Joffroy sign). 
•   Poor convergence (Möbius sign). 
•   Extraocular muscle restriction (Ballet sign). 
•   Relative afferent pupillary defect. 
•   Visual field loss. 
•   Color vision deficiency. 
GD •   Heat intolerance. 
•   Restlessness. 
•   Fatigability. 
•   Increased appetite. 
•   Weight loss. 
•   Palpitations. 
•   Diarrhea. 
•   Amenorrhea. 
•   Irregular menstrual period. 
•   Goiter (simple and diffuse). 
•   Tremor. 
•   Arrhythmia (e.g. atrial fibrillation). 
•   Proximal muscle weakness. 
•   Thyroid acropachy (clubbing of the fingers and toes).  
•   Pretibial myxedema (a nodular or diffuse thickening of the 
pretibial skin). 
 
Conclusion 
There are multiple systemic diseases and 
therapies that are associated with ocular 
problems in all parts of the eye. A high index of 
suspicion is necessary to actively detect these 
conditions and refer patients timeously when 
indicated to allow the highest possibility of visual 
recovery. In addition, the role of retinal 
microvascular analysis, including retinal vascular 
caliber, fractals, arteriovenous ratio and flicker 
light-induced retina-arterial vasodilation, should 
be further pursued to improve the prediction, 
prevention and management of cardiovascular 
disease worldwide. 
 
What are known already: What this study adds/ highlights: 
•   Ocular diseases with cardiovascular associations include 
diabetic retinopathy, retinal venous and artery occlusion, 
hypertensive retinopathy, transient monocular visual field loss, 
and ischemic optic neuropathy. 
•   Ocular diseases with autoimmune assocations include uveitis, 
dry eye disease/ keratoconjunctivitis sicca, ocular graft-versus-
host-disease, peripheral ulcerative keratitis, sclerosing 
keratitis, calcific band keratopathy, scleritis, and Graves’ 
Ophthalmopathy. 
•   The commoner systemic diseases that have ocular associations 
are cardiovascular diseases (diabetes mellitus, hypertension 
and hyperlipidemia) and autoimmune or inflammatory 
diseases (rheumatoid arthritis, spondyloarthropathies, 
inflammatory bowel diseases, Wegener granulomatosis ). 
•   Vision is actually considered more 
important than lifespan or loss of a 
limb in the majority of people. 
•   Retinal microvascular analysis has 
the potential to develop an 
important role in the prediction, 
prevention, monitoring and 
prognosis of cardiovascular 
diseases. 
•   Certain medications (systemic, 
intraocular and topical) are 
important but often-overlooked 
causes of uveitis. 
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